Evidence map›Paper›PMID 39062056›Full record

ReviewBiomedicines2024

Bioactive Peptides and Other Immunomodulators of Mushroom Origin.

Beata Drzewiecka, Joanna Wessely-Szponder, Michał Świeca, Paula Espinal, Ester Fusté, Eric Fernández-De La Cruz

Abstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Antioxidants (Basel, Switzerland) · 2025
    Review
  5. Lion's Mane Mushroom (Nutrients · 2025
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Beata DrzewieckaSub-Department of Pathophysiology, Department of Preclinical Veterinary Sciences, Faculty of Veterinary Medicine, University of Life Sciences, 20-033 Lublin, Poland.ORCID 0000-0001-5862-4615
Joanna Wessely-SzponderSub-Department of Pathophysiology, Department of Preclinical Veterinary Sciences, Faculty of Veterinary Medicine, University of Life Sciences, 20-033 Lublin, Poland.ORCID 0000-0002-8815-0630
Michał ŚwiecaDepartment of Biochemistry and Food Chemistry, University of Life Sciences, Skromna Str. 8, 20-704 Lublin, Poland.ORCID 0000-0002-6513-8399
Paula EspinalDepartment of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, University of Barcelona, 08907 Barcelona, Spain.ORCID 0000-0002-1014-8936
Ester FustéDepartment of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, University of Barcelona, 08907 Barcelona, Spain.ORCID 0000-0002-3561-9765
Eric Fernández-De La CruzDepartment of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, University of Barcelona, 08907 Barcelona, Spain.

Funding

National Science Centre, Poland, OPUS no. 2022/45/B/NZ9/01892
6 · The paper itself

Abstract

For centuries, humans have used mushrooms as both food and pro-health supplements. Mushrooms, especially those related to the functions of the human immune system, are rich in dietary fiber, minerals, essential amino acids, and various bioactive compounds and have significant health-promoting properties. Immunoregulatory compounds in mushrooms include lectins, terpenes, terpenoids, polysaccharides, and fungal immunomodulatory proteins (FIPs). The distribution of these compounds varies from one species of mushroom to another, and their immunomodulatory activities depend on the core structures and chemical modifications in the composition of the fractions. In this review, we describe active compounds from medical mushrooms. We summarize potential mechanisms for their in vitro and in vivo activities and detail approaches used in developing and applying bioactive compounds from mushrooms. Finally, we discuss applications of fungal peptides and highlight areas that require improvement before the widespread use of those compounds as therapeutic agents and explore the status of clinical studies on the immunomodulatory activities of mushrooms and their products, as well as the prospect of clinical application of AMPs as 'drug-like' compounds with great potential for treatment of non-healing chronic wounds and multiresistant infections.

Indexed as

antimicrobial peptidesbioactive peptidesfungal immunomodulatory compoundsimmuno-modulationmedical mushroomstherapeutic peptides

Identifiers

PMID39062056
PMCPMC11274834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.